Marc Schwartz, MD
Hematology & Oncology · Aurora, CONPI 1518385467
Payments from drug & device makers
Across 33 payments — averaging $2156.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$45K
- AbbVie$15K
- National Marrow Donor Program$4K
- Jazz Pharmaceuticals Inc.$4K
- Gilead$2K
- Novartis$400
- plus $150 from 2 others
What the payments were for
- Consulting fees$20,72599%
- Food & beverage$2301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 18 | $45,462 |
| AbbVie | 3 | $14,671 |
| National Marrow Donor Program | 6 | $4,338 |
| Jazz Pharmaceuticals Inc. | 2 | $3,744 |
| Gilead | 1 | $2,390 |
| Novartis | 1 | $400 |
| Karyopharm Therapeutics Inc. | 1 | $131 |
| Amgen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,154 in reported general payments places this provider in the 60th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 51 | $1,046,850 |
| XospataGilteritinib Fumarate | 13 | $256,522 |
| SprycelDasatinib | 23 | $234,813 |
| PrevymisLetermovir | 11 | $70,397 |
| Acyclovir | 85 | $3,316 |
| Ursodiol | 22 | $1,773 |
| Fluconazole | 17 | $1,088 |
| Tacrolimus | 16 | $767 |
| Dapsone | 15 | $616 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 38 | $250 |
| Sodium Chloride0.9 % Sodium Chloride | 14 | $80 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Aurora
- John BurkeAurora$25.4M
- Elena ShagisultanovaAurora$22.4M
- Elaine LamAurora$12.6M
- Daniel PollyeaAurora$9.4M
- Manali KamdarAurora$8.9M
- Jennifer DiamondAurora$7.1M
- Thomas FlaigAurora$5.9M
- Ryan WeightAurora$2.9M
- Sujatha NallapareddyAurora$1.7M
- Sami DiabAurora$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.